Hormones and Cardiovascular Disease
Director: Pierre-Yves Scarabin

Hormones and Cardiovascular Disease
Director: Pierre-Yves Scarabin

Hormones and Cardiovascular Disease
Director: Pierre-Yves Scarabin

 

Why the SNAC ?

 

The final results of the ESTHER study (Canonico et al, Circulation, 2007) showed a 4-fold increased VTE risk among postmenopausal women using transdermal estrogens combined with norpregnane derivatives. 

 

The lack of data on the potential thrombogenic effect of norpregnane derivatives prompted us to undertake the Study of NorpregnAnes on Coagulation (SNAC).

 

Study Design

 

SNAC is a cross-sectional study among healthy postmenopausal women. Effect of activated protein C (APC) on endogenous thrombin potential (ETP) together with haemostatic variables are investigated in the plasma of women using transdermal estrogens combined with either micronised progesterone or norpregnane derivatives in comparison with non-users.   

 

Participants to the SNAC study ?

 

Clinical center :

 

Health Check-up Center in Paris (Centre d’Investigations Pré-cliniques (IPC), Paris)

 

Haemostatic tests and DNA bank :  Haematology Department of the Georges Pompidou European Hospital (HEGP) in Paris (Martine Alhenc-Gélas)

 

Coordinating center : Inserm U780 (M Canonico, G Plu-Bureau and PY Scarabin).

 

Funding

The study is supported by Inserm and by a grant from the « Mutuelle Générale de l’Education Nationale (MGEN). 

© Esther 2019